

Please type a plus sign (+) inside this box.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

#2

+ 3/13/02

23

01/02/2002

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	New Application
				Filing Date	
				First Named Inventor	Becker, et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	R0079C-REG

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
TNT ✓	A1	3,960,861		Danilewicz, et al	June 1, 1976	260/256.4
	A2	4,044,136		Danilewicz, et al	Aug. 23, 1977	424/251
	A3	4,686,228		Campbell, et al	Aug. 11, 1987	514/307
TNT ✓	A4	6,103,738		Collis, et al	Aug. 15, 2000	514/311

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
TNT ✓	B1 ✓	WO	98/30560	A1	Pfizer	July 16, 1998	
TNT ✓	B2 ✓	GB	1,062,357		Pfizer	March 22, 1967	
TNT ✓	B3 ✓	DE	27,57,925	A1	Bayer AG	June 28, 1979	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
TNT ✓	C1	GUPTA, et al., "Drugs Acting on the Central Nervous System. Syntheses of Substituted Quinazolones and Quanazolines and Triazepino- and Triazocinoquinazolones," <i>J. Med. Chem.</i> , 1968, 392-395, 11(2),				
	C2	LEONARDI, et al., "Synthesis, Pharmacological Evaluation, and Structure - Activity Relationship and Quantitative Structure - Activity Relationship Studies on Novel Derivatives of 2,4-Diamino-6,7-dimethoxyquinazoline α_1 -Adrenoceptor Antagonists", <i>J. Med. Chem.</i> , 1999, 427-437, 42 .				
	C3	MENZIANI, et al., , "Relevance of Theoretical Molecular Descriptors in Quantitative Structure - Activity Relationship Analysis of α_1 -Adrenergic Receptor Antagonists," <i>Bioorg., Med. Chem.</i> , 1999, 2437-2451, 7(11) ,				
	C4	VILLALORGO, et al., "Solid-Phase Synthesis of 3H-Quinazolin-4-ones Based on an Aza Wittig-Mediated annulation Strategy", <i>Synlett</i> , 1998, 1405-1407, 12.				
TNT ✓	C5	WOLLWEBER, et al., "3-Amino-2H-1,2,4-benzothiadiazin-1,1-dioxide mit antihypertensiver und potentieller diabetogener Wirkung", <i>Arzneim.-Forsch.</i> , 1981, 279-88, 31(2).				

Examiner Signature	<i>Wlon</i>	Date Considered	3/31/03
--------------------	-------------	-----------------	---------

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<i>Complete If Known</i>	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/040,319
		Filing Date	January 2, 2002
		First Named Inventor	Beck r, Cyrus K phra t al.
		Group Art Unit	1614
		Examiner Name	TBA
Sheet	1	of	1
			Attorney Docket Number
			R0079C-REG

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature		Dat Considered	9/27/03
-----------------------	---	-------------------	---------

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231